ACIU
NASDAQ
$2.25
AC Immune SA (ACIU)
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company is headquartered in Lausanne, Switzerland.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $8.52 (+278.67%)
Market Cap
$233M
Free Cash Flow Yield
-27.55%
Beta (5Y)
1.03
Price Chart
Valuation
Market Cap$233M
Forward P/E11.24
P/S65.70
P/B6.24
Profitability
Total Revenue (TTM)$4.63M
Gross Profit (TTM)-$61M
EBITDA-$81M
Operating Margin-1322%
EPS-$0.83
Financial Health
Debt-to-Equity13.6%
Free Cash Flow Yield-27.55%
Growth & Risk
EPS 5Y CAGR-4.76%
Revenue 5Y CAGR+6.29%
FCF 5Y CAGR-3.18%
Beta (5Y)1.03
Sharpe Ratio0.44